SCHEMBL4899229

SCHEMBL4899229

CCOC(=O)c1noc(C)c1C(=O)c1ccc(SC)cc1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.52
HTT P42858 2/20 0.47
MAPT P10636 3/20 0.44
MEN1 O00255 1/20 0.44
LMNA P02545 1/20 0.44
TSHR P16473 1/20 0.44
KMT2A Q03164 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
MLYCD O95822 1/20 0.42
SLC26A6 Q9BXS9 1/20 0.42
HRH2 P25021 1/20 0.39
HRH1 P35367 1/20 0.39
MAPK1 P28482 1/20 0.39
PTGS2 P35354 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
TP53 P04637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3032322 0.87 ALDH1A1 (0.53) ALDH1A1HTTLMNAKMT2ASMN1; SMN2
SCHEMBL3033421 0.84 HTT (0.58) ALDH1A1HTTMAPTMEN1LMNA
SCHEMBL3032698 0.84 ALDH1A1 (0.54) ALDH1A1HTTMAPTLMNASMN1; SMN2
SCHEMBL994810 0.84 HTT (0.54) ALDH1A1HTTMAPTLMNATSHR
SCHEMBL1374393 0.83 ALDH1A1 (0.53) ALDH1A1HTTMAPTLMNASMN1; SMN2
SCHEMBL5209802 0.83 ALDH1A1 (0.52) ALDH1A1HTTMAPTLMNAKMT2A
SCHEMBL3037380 0.77 ALDH1A1 (0.52) ALDH1A1HTTMAPTMEN1KMT2A
SCHEMBL3036700 0.77 HTT (0.56) ALDH1A1HTTTSHRSMN1; SMN2NPSR1
SCHEMBL2822374 0.76 HTT (0.55) ALDH1A1HTTLMNATSHRMLYCD
SCHEMBL3038647 0.76 ALDH1A1 (0.49) ALDH1A1HTTMAPTMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269235-A1 PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS DAL PIAZ VITTORIO 2008-10-30 US disclosed
EP-1503992-A1 PYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE4 INHIBITORS Almirall Prodesfarma, S.A. (ES) 2005-02-09 EP disclosed
WO-2003097613-A1 PYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE4 INHIBITORS ALMIRALL PRODESFARMA SA (ES) 2003-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269235-A1 PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS PDE4A, PDE3A, PDE4B ALDH1A1 525/4885HTT 4780/4885MAPT 3692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.